Table of Contents
Circulating Tumour DNA (ctDNA): How Blood Tests Track Cancer
By Dr. Gajendra Kumar Himanshu
Circulating tumour DNA (ctDNA) is microscopic pieces of genetic material secreted by cancer cells into the blood. A ctDNA blood test, often called a liquid biopsy, can help clinicians track the response of cancer to treatment, detect minimal residual disease (MRD), identify specific genetic changes, and sometimes discover cancer recurrence earlier than imaging tests. It's a complement, but not a replacement, for traditional scans and tissue samples.
In this blog, we explain circulating tumour DNA (ctDNA), how the sophisticated blood test works, when doctors recommend it, its benefits and limitations, and how it is transforming cancer monitoring. You'll also learn how ctDNA is becoming an important aspect of individualized care for cancer patients.
Why Is ctDNA Important for Cancer Care?
Surgery, chemotherapy, or radiation do not mark the end of cancer treatment. Doctors also need dependable ways to tell if treatment is effective, if cancer has returned or if further therapy is needed. Traditionally, this has been done with imaging scans and tissue samples, but these procedures may not always detect tiny quantities of residual malignancy.
Another approach to monitoring cancer is by circulating tumor DNA. Tumour cells shed little fragments of their DNA into the bloodstream; therefore, a single blood sample can tell us a lot about the disease without the need for an intrusive surgery. The method allows doctors to watch the cancer change over time and make better-informed decisions about treatment.
What is ctDNA or Circulating Tumor DNA?
Every cell in the body spontaneously breaks down, releasing little pieces of DNA into the bloodstream. Cancer cells do the same, but the DNA they release has genetic modifications that are particular to the cancer. These bits are called circulating tumor DNA (ctDNA).
These bits of DNA can be identified and studied in a blood sample using very sensitive lab techniques. It is often called a liquid biopsy, as it looks for DNA related to tumours in the blood.
A liquid biopsy needs only a blood sample, whereas a standard biopsy takes tissue directly from the tumour, making it harder to do at different points in treatment.
How Does a ctDNA Blood Test Follow Cancer?
The ctDNA test provides doctors a real-time window into the activities of the malignancy. Depending on the type of cancer and clinical scenario, it can help in treatment decision-making in many ways.
It might help to:
- Check on the progress of the treatment
- Detect residual illness (MRD) following therapy
- Detect cancer recurrence before symptoms develop
- Identify particular gene mutations that guide targeted therapy
- Trace the development of treatment resistance
ctDNA provides an additional level of information to build a more complete picture of the patient's disease, rather than replacing imaging studies.
Which Cancers Can ctDNA Be Used to Monitor?
Research and clinical application of ctDNA continue to grow. Today, ctDNA testing is performed in select patients with numerous forms of cancer, including:
- Cancer of the colon or rectum
- Lung carcinoma
- Breast carcinoma
- Melanoma, malignant
- Ovarian carcinoma
- Bladder cancer
The utilization is dependent upon the type of cancer, stage of disease, lab technology available, and current clinical standards.
Advantages of ctDNA Testing
One of the key benefits of ctDNA testing is that it can be conducted with a single blood sample in most cases, avoiding the need for recurrent tissue biopsies.
Advantage | Why It's Important |
|---|---|
Minimally invasive | All you need is a blood sample. |
Repeatable | Can be done repeatedly during the course of treatment |
Personalised | Identifies genetic alterations unique to tumours |
Early surveillance | May identify recurrence prior to imaging findings. |
Advice on treatment | Helps in finding mutations for targeted treatments |
These advantages make ctDNA a valuable tool in precision oncology, where treatment is customized to the biology of each patient's cancer.
What Are the Limitations of ctDNA?
While ctDNA testing holds promise, it's not right for every patient or every form of cancer.
Some malignancies, in their early stages, release very little tumor DNA into the blood and hence are hard to detect. Also, not all tumours release detectable ctDNA, and a negative result does not suggest that cancer is not present.
For these reasons, doctors interpret ctDNA results according to physical examination, imaging investigations, pathology reports, and other laboratory testing. The test is most useful when it is part of an overall cancer management plan and not employed as a stand-alone study.
Who Can Benefit from ctDNA Testing?
If you are being treated for specific cancers, or need to be closely monitored after treatment is complete, your oncologist may recommend ctDNA testing.
The test can be considered in patients requiring:
- Monitoring of reaction to therapy
- Minimal residual disease evaluation
- Assessment of probable cancer recurrence
- Identifying mutations for targeted therapy
- Continuous disease monitoring in selected malignancies
Whether ctDNA testing is right for you will depend on your diagnosis, treatment history, and unique clinical circumstances.
If you want to read more about cancer treatment, then you can visit the National Cancer Institute.
Consult Today
To find out if circulating tumour DNA (ctDNA) testing is a possible option for your cancer treatment, please contact the oncology specialists at Oncare Cancer Hospital. They can talk to you about how this advanced blood test fits into your personalized treatment and follow-up strategy.
Disclaimer
This information is solely for educational reasons and is not a substitute for professional medical advice, diagnosis, or treatment. If you have questions concerning ctDNA testing or your cancer treatment, please talk to your doctor or a trained oncologist.
Frequently Asked Questions
ctDNA is tiny bits of DNA that are released into the blood from cancer cells. Blood tests can be used to view these fragments to help track the malignancy.
No, a ctDNA test is a liquid biopsy from a blood sample, while a tissue biopsy entails taking a sample directly from the tumour. Both exams give complementary and different information.
Yes. In certain people, ctDNA testing can detect early signals of cancer recurrence before they can be seen on imaging scans; however, it is used in conjunction with other diagnostic techniques.
Not always. For some malignancies, there is very little tumour DNA shed into the bloodstream. Your doctor will consider the ctDNA results in conjunction with the scans, exams, and other clinical information.
Written and Verified by:
Dr. Gajendra Kumar Himanshu Exp: 10 Yr
Medical Officer
Book an Appointment
Related Blogs
Cancer and Blood Clots (DVT and Pulmonary Embolism): Risks and Prevention
Cancer is strongly related to blood clots because cancer and some cancer treatments can increase the likelihood of the body developing clots. These clots can occur in the deep veins of the legs (deep vein thrombosis, or DVT) or travel to the lungs (pulmonary embolism, or PE). Early identification, preventive actions, and timely treatment can greatly decrease problems and increase patient safety.
Malignant Ascites: Managing Fluid Build-Up in the Abdomen
Why fluid collects in the abdomen in advanced cancer, the symptoms to watch for, the tests used to diagnose it, the drainage and drug treatments available, and when to seek urgent medical help.
Oligometastatic Cancer: When Limited Spread Changes the Plan
What oligometastatic cancer is, how it differs from widespread metastatic disease, the scans used to diagnose it, how local and systemic treatment are combined, and which patients may benefit from a more aggressive approach.
Recovery After Pancreatic Cancer Surgery (Whipple): A Home Care Guide
What recovery looks like in the first weeks after a Whipple procedure, the digestive and appetite changes to expect, nutrition and wound care at home, how to rebuild activity safely, and when to call your care team.